Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
暂无分享,去创建一个
Deo Kumar Srivastava | Ching-Hon Pui | Varsha Gandhi | William Plunkett | F. Behm | S. Raimondi | C. Pui | D. Srivastava | R. Ribeiro | W. Plunkett | V. Gandhi | J. Rubnitz | C. Stewart | K. Crews | Susana C Raimondi | Raul C Ribeiro | Jeffrey E Rubnitz | Clinton F Stewart | B. Razzouk | X. Tong | Kristine R Crews | Bassem I Razzouk | Xin Tong | Fred G Behm
[1] S. Raimondi,et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] F. Berthold,et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Niemeyer,et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93 , 2001, Leukemia.
[4] S. Raimondi,et al. Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects , 2000, Leukemia.
[5] G. Henze,et al. Definition of a standard‐risk group in children with AML , 1999, British journal of haematology.
[6] J. Buckley,et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. , 1996, Blood.
[7] J. Krischer,et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood , 1996 .
[8] Juliusson,et al. Cellular pharmacokinetics of 2-chloro-2'-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] R. Krance,et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. , 1994, Blood.
[10] M. Schell,et al. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] W. Plunkett,et al. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. , 1992, Cancer research.
[12] G. Juliusson,et al. On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. , 1991, Cancer research.
[13] M. Schell,et al. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] W. Plunkett,et al. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. , 1989, Blood.
[15] E. Estey,et al. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] W. Plunkett,et al. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. , 1988, Cancer research.
[17] E. Estey,et al. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. , 1987, Leukemia.
[18] E. Estey,et al. Saturation of 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate Accumulation in Leukemia Cells during High-Dose 1-β-d-Arabinofuranosylcytosine Therapy , 1987 .
[19] W. Plunkett,et al. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. , 1987, Cancer treatment reports.
[20] Jan Liliemark,et al. Relationship of 1-β-d-Arabinofuranosylcytosine in Plasma to 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate Levels in Leukemic Cells during Treatment with High-Dose 1-β-d-Arabinofuranosylcytosine , 1985 .
[21] W. Plunkett,et al. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. , 1980, Cancer research.
[22] R. Momparler,et al. Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. , 1968, The Journal of biological chemistry.
[23] J. Buckley,et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. , 2001, Blood.
[24] G. Reaman,et al. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] E. Estey,et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. , 1996, Leukemia.
[26] M. Ratain,et al. Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] E. Estey,et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. , 1996, Blood.
[28] E. Estey,et al. Biochemical modulation of arabinosylcytosine for therapy of leukemias. , 1993, Leukemia & lymphoma.
[29] E. Estey,et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] W. Plunkett,et al. Separation of 1-β-d-arabinofuranosylcytosine 5′-triphosphate and 9-β-d-arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemia cells by high-performance liquid chromatography , 1987 .
[31] E. Estey,et al. Pharmacologically directed ara-C therapy for refractory leukemia. , 1985, Seminars in oncology.